Since nesfatin-1 acts as an anorexigenic adipokine and pre-clinical evidence suggests its role in preserving bone density, it could serve as a promising target for the treatment of both obesity as well as osteoporosis. This evidence concerns the gene NUCB2 and obesity due to melanocortin 4 receptor deficiency.